Wide Ranks

EDSA

Edesa Biotech, Inc.

2.30

Top Statistics
Market Cap 7 M Forward PE -1.19 Revenue Growth 0.00 %
Current Ratio 1.29 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.6610 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 2 M Total Cash Per Share 0.6280 Total Debt 38817
Total Debt To Equity 1.35 Current Ratio 1.29 Book Value Per Share 0.8830
All Measures
Short Ratio 111.00 % Message Board Id finmb_313039720 Shares Short Prior Month 19836
Return On Equity -1.29 City Markham Uuid feae63c9-ecbf-391a-bfe7-79648f666a2a
Previous Close 2.21 First Trade Date Epoch Utc 1 B Book Value 0.8830
Beta 0.8380 Total Debt 38817 Volume 18961
Price To Book 2.60 Last Split Date 1 B Fifty Two Week Low 2.05
Total Cash Per Share 0.6280 Shares Short Previous Month Date 1 B Target Median Price 20.50
Max Age 86400 Sand P52 Week Change 0.3133 Target Mean Price 20.50
Net Income To Common -6928337 Short Percent Of Float 0.0180 Implied Shares Outstanding 3 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 19070
Average Volume10days 19070 Total Cash 2 M Next Fiscal Year End 1 B
Held Percent Insiders 0.3302 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 2.21 Target Low Price 20.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 3.42 Open 2.35
Free Cashflow -3770207 State ON Dividend Yield 0.00 %
Return On Assets -0.7151 Time Zone Short Name EST Trailing Eps -19.78
Day Low 2.25 Address1 100 Spy Court Shares Outstanding 3 M
Price Hint 4 Target High Price 21.00 Website https://www.edesabiotech.com
52 Week Change -0.3030 Average Volume 23906 Forward Eps -1.93
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 109.80 %
Last Split Factor 1:7 Regular Market Day High 2.37 Is_sp_500 False
Profit Margins 0.00 % Debt To Equity 1.35 Fifty Two Week High 6.46
Day High 2.37 Shares Short 48461 Regular Market Open 2.35
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0149 Operating Cashflow -5391188 Currency USD
Time Zone Full Name America/New_York Market Cap 7 M Is_nasdaq_100 False
Zip L3R 5H6 Quote Type EQUITY Industry Biotechnology
Long Name Edesa Biotech, Inc. Regular Market Day Low 2.25 Held Percent Institutions 0.1220
Current Price 2.30 Enterprise To Ebitda -0.6610 Financial Currency USD
Current Ratio 1.29 Industry Disp Biotechnology Number Of Analyst Opinions 2
Country Canada Float Shares 2 M Two Hundred Day Average 4.25
Enterprise Value 5 M Forward PE -1.19 Regular Market Volume 18961
Ebitda -8270169 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases.

Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.

The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo.

It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions.

The company was founded in 2015 and is headquartered in Markham, Canada.